Opinion: FDA’s “Hypocrisy” on Flavored Vapes Protects Cigarettes
Over the last decade, the U.S. Food and Drug Administration (FDA) has faced mounting criticism for its regulatory stance on vaping, particularly its aggressive policing of flavored products. Critics argue this approach has created a “regulatory moat” that inadvertently protects the combustible cigarette market while leaving adult smokers with fewer, less appealing alternatives to quit. The result, they say, is a thriving gray market for unregulated vapes and a missed opportunity for public health.
The core of the argument lies in harm reduction. While not harmless, vaping is widely recognized by bodies like the UK’s Royal College of Physicians as being significantly less harmful than smoking—estimated at unlikely to exceed 5% of the risk. Flavored vapes are often cited as a crucial tool for smokers transitioning away from cigarettes. Yet, the FDA has consistently rejected applications for flavored vaping products, choosing to fight the market rather than authorize products that meet safety standards.
This de facto prohibition hasn’t curbed demand; instead, it has driven consumers toward riskier, unregulated products. Even the FDA acknowledges that over half of all vapes sold in the U.S. are unauthorized flavored products. Critics contend that by failing to provide transparent product reviews and authorizations, the agency leaves consumers with no safety information, benefiting black-market dealers.
The FDA justifies its stance by citing youth nicotine use. However, data indicates that teen nicotine use has been falling for decades, and youth vaping rates peaked in 2019 and have since declined. The perceived “epidemic” was largely a shift from cigarettes to vapes amidst an overall drop in nicotine use.
A stark disparity exists in product approvals. To date, the FDA has authorized only 39 vaping products from just four companies. In contrast, between 2018 and 2022, the agency approved nearly 900 additional cigarettes, bringing the total to 3,910. There are now roughly 100 times more approved cigarettes than reduced-risk vape options. This imbalance, critics argue, fails the agency’s own standard of protecting public health by denying products that dramatically reduce toxin exposure.
The FDA’s decisions also have a ripple effect on state laws. States like Wisconsin now ban any vape not authorized by the FDA, further cutting off smokers from potential cessation tools. The argument remains that prohibition doesn’t work; instead of fighting consumer preferences, the FDA should focus on regulating for safety and quality to ensure adult smokers have access to effective alternatives.
- Reference: Vape hypocrisy at the FDA
- South Korea Escalates Tobacco Warnings with Blunt, Fatalistic Labels - June 22, 2026
- Magnolia Commissioner Proposes Ordinance to Ban Vape Shops - June 22, 2026
- Belarus Moves to Ban Vape and E-Cigarette Advertising Under New Bill - June 22, 2026
